BILL Holdings Option Alert: May 16 $67.5 Puts at the Bid: 1000 vs 1244 OI

BILL Holdings Option Alert: May 16 $67.5 Puts at the Bid: 1000 @ $13.2 vs 1244 OI; Ref=$56.09

BILL Holdings (NYSE:BILL) 주식

BILL HOLDINGS INC

BILL Holdings

BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.

Bill.com Holdings

benzingaai2023_modern_computer_screen_with_stock_chart_stock__6576dd35-b4b0-42d8-8403-ba4e9845ab24_3

News

Hedge Funds

Trading Ideas

BILL

CFLT

CRMD

ICLR

MSTR

NVDA

RING

WOLF

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 기술 노출을 재편했다. 미국 증권 거래 위원회에 제출된 새로운 13-F 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:

엘리엇 인베스트먼트가 울프스피드 주식을 매수하고 4분기에는 엔비디아 풋 옵션에 베팅

Young,Indian,Businessman,Holding,Phone,Reading,Bank,Receipt,Calculating,Taxes,

Earnings Beats

Long Ideas

Options

Movers

겉보기에는 결제 처리 전문 회사인 빌 홀딩스(빌닷컴)(NYSE:BILL)이 지난주처럼 폭락할 이유가 없어 보였다. 목요일, 이 회사는 2023 회계년도 2분기 재무 결과를 발표하며 3억 6,255만 달러의 매출과 주당 56센트의 조정된 순이익을 기록했다. 이 수치는 각각 3억 6,023만 달러와 46센트라는 애널리스트들의 컨센서스 예상치를 모두 초과한 결과이다. 그럼에도 불구하고 빌닷컴의 주식은 실적 결과 발표 후 급락했다.

옵션 코너: 빌 홀딩스의 실적 후 폭락으로 투기자들에게 할인된 매수 거래 기회 제공

benzingaai2023_stock_market_charts_on_multiple_computer_scree_03ada781-be05-460b-a6af-38988bc7658b_1

Earnings

Guidance

After-Hours Center

빌 홀딩스(NYSE:BILL)는 목요일(6일) 2분기 재무 실적을 발표한 후 주가가 시간외 거래에서 급락했다. 실적 보고서 요약은 다음과 같다.

빌 홀딩스, 2분기 실적 발표 이후 주가 29% 급락한 이유는?

BILL Holdings Inc

BILL IDENTITY LTD by BILL IDENTITY LTD

Billerud AB

BillionHappiness

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy and lowers the price target from $54 to $45.

Price Target

Analyst Ratings

RCKT

Chardan Capital Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $45

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and lowers the price target from $28 to $25.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $25

UBS analyst Trung Huynh maintains Celldex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLDX#NASDAQ">CLDX</a>) with a Buy and lowers the price target from $44 to $38.

CLDX

UBS Maintains Buy on Celldex Therapeutics, Lowers Price Target to $38

Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) has outperformed the market over the past 20 years by 8.79% on an annualized basis producing an average annual return of 16.95%. Currently, Domino's Pizza has a market capitalization of $16.40 billion. 
Buying $1000 In DPZ: If an investor had bought $1000 of DPZ stock 20 years ago, it would be worth $22,913.88 today based on a price of $478.90 for DPZ at the time of writing.
<h3>Domino's Pizza's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746829811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Domino's Pizza 20 Years Ago Would Be Worth Today

UBS analyst Christopher Schoell maintains Cogent Comms Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCOI#NASDAQ">CCOI</a>) with a Buy and lowers the price target from $102 to $75.

CCOI

UBS Maintains Buy on Cogent Comms Hldgs, Lowers Price Target to $75

UBS analyst Josh Silverstein maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Buy and lowers the price target from $32 to $30.

CTRA

UBS Maintains Buy on Coterra Energy, Lowers Price Target to $30

UBS analyst Steven Fisher maintains Jacobs Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) with a Buy and lowers the price target from $154 to $152.

UBS Maintains Buy on Jacobs Solutions, Lowers Price Target to $152

UBS analyst Trung Huynh maintains Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy and lowers the price target from $110 to $109.

INSM

UBS Maintains Buy on Insmed, Lowers Price Target to $109

UBS analyst Peter Grom maintains Molson Coors Beverage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) with a Neutral and lowers the price target from $63 to $59.

UBS Maintains Neutral on Molson Coors Beverage, Lowers Price Target to $59

UBS analyst Dan Leonard maintains Bio-Techne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECH#NASDAQ">TECH</a>) with a Buy and lowers the price target from $95 to $70.

TECH

UBS Maintains Buy on Bio-Techne, Lowers Price Target to $70

UBS analyst John Lovallo maintains Trex Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TREX#NYSE">TREX</a>) with a Neutral and lowers the price target from $74 to $72.

TREX

UBS Maintains Neutral on Trex Co, Lowers Price Target to $72

UBS analyst Kevin Caliendo maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $27 to $25.

XRAY

UBS Maintains Buy on Dentsply Sirona, Lowers Price Target to $25

UBS analyst Kunal Madhukar maintains ZipRecruiter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIP#NYSE">ZIP</a>) with a Neutral and lowers the price target from $7 to $6.

UBS Maintains Neutral on ZipRecruiter, Lowers Price Target to $6

UBS analyst Seth Gilbert maintains Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) with a Neutral and lowers the price target from $3.5 to $2.

VERI

UBS Maintains Neutral on Veritone, Lowers Price Target to $2

UBS analyst Danielle Antalffy maintains Treace Medical Concepts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) with a Neutral and lowers the price target from $10 to $8.6.

TMCI

UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6

UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 12.37%. Currently, UnitedHealth Group has a market capitalization of $344.73 billion. 
Buying $1000 In UNH: If an investor had bought $1000 of UNH stock 10 years ago, it would be worth $3,285.34 today based on a price of $380.02 for UNH at the time of writing.
<h3>UnitedHealth Group's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746828911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning UnitedHealth Group Stock In The Last 10 Years

UBS analyst Kevin Mcveigh maintains Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) with a Neutral and lowers the price target from $2.95 to $1.9.

UBS Maintains Neutral on Rackspace Technology, Lowers Price Target to $1.9

UBS analyst Chris Zhang maintains International Money (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMXI#NASDAQ">IMXI</a>) with a Neutral and lowers the price target from $17 to $12.

IMXI

UBS Maintains Neutral on International Money, Lowers Price Target to $12

UBS analyst Timothy Arcuri maintains Allegro Microsystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGM#NASDAQ">ALGM</a>) with a Buy and raises the price target from $22 to $25.

ALGM

UBS Maintains Buy on Allegro Microsystems, Raises Price Target to $25

UBS analyst Peter Grom maintains Kenvue (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) with a Neutral and raises the price target from $24 to $25.

Comments

BILL Holdings

Unusual Options Activity for

뉴스

파트너 / 기고자

벤징가 글로벌